Title
Home A
Presented By:
Edward Gammans

Value of WatchBP
 World’s Largest Manufacturer of Non Contact Thermometers
(Brands include J & J and Calpol)
 World’s 2 nd Largest Manufacturer of Blood Pressure Monitors
 Presence in over 180 Countries World Wide
 WatchBP Range 2 Years ahead of the competition
© 2011All Rights Reserved. No copy and distribution without permission
*Approximate Figures

Value of WatchBP
 Safe Study / Trial
(Compared Pulse – ECG in Primary Care) *
GP’s Results were Sensitivity 80% - Specificity 92%
PN’s Results were Sensitivity 77% - Specificity 85%
Overall Results were Sensitivity 78% - Specificity 88%
 Wiesel
(New York - ISH)
**
Results were Sensitivity 97% - Specificity 89%

Stergiou
(Athens - ESH)
***
Results were Sensitivity 100% - Specificity 89%
Overall Results were Sensitivity 97-100% - Specificity 89%
© 2011All Rights Reserved. No copy and distribution without permission

(Wiesel, 2004)
(Stergiou, 2009)
(Wiesel, 2009)
(Marazzi, 2011)
Patients
450
72
405
503
Readings used
1
2
1
2
3
1
3
3
Readings needed for diagnosis
1
2
1
1
2
1
3
3
Sensitivity
(95% CI)
1
1
Specificity
(95% CI)
0.84
0.92
0.93 (0.74–0.99) 0.89 (0.76–0.96)
1 (0.84-1.00) 0.76 (0.60–0.87)
1.00 (0.84–1.00) 0.89 (0.75–0.96)
0.95 (0.93-0.98)
0.97 (0.91-0.99)
0.92
0.86 (0.84-0.89)
0.89 (0.85-0.92)
0.97
Device compared with 12-lead ECG performed and read by a consultant

AF+100 AF- 89
Hobbs et al. Health Technology Assessment 2005; Vol. 9: No. 40

• GP population 10M of ≥ 55y, AF prevalence of 4.4%
ECG
AF+ AFpp
(87,81%) AF+
AF-
382.800
57.200
1.816.400
7.743.600
WatchBP
(100, 89%)
With WatchBP:
AF+
AF-
AF+
440.000
0
AF-
1.051.600
8.508.400
57,200 AF patients more diagnosed
764,800 patients less false positives

•
Liable to observer bias
• Dependent of GP’s/nurses who know the guidelines
• Dependent of GP’s/nurses who adhere to the guidelines

A Patient with AF has 35% chance of getting stroke (4% per year)
Time (yrs)
Task Force for the Management of Atrial Fibrillation of the European
Society of Cardiology (ESC). Europace 2010;12:1360-1420.

Untreated (540)
Systolic
175
170
165
160
140
0
• 5 mmHg
• 7 mmHg
1 2
Meting
3
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
 GP Surgery:
Normal Blood pressure check
If Afib Symbol appears – 3/3 Will confirm AF
Any uncertainty then the patient should be sent home with a device to perform a 7 day diagnostic programme.
 Home:
This is also advised if the patient complains of symptoms that are undiagnosed - chest pains, dizziness, falling over and when asymptomatic paroxysmal AF is expected.
This would result in approx 28 readings – the equivalent of 28 visits to the clinician
NB: If the patient is feeling unwell at a specific time during the day they can also perform a one of measurement on casual mode.
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
(New Guidelines to be published in Sept 2011)
 BHS are represented at both the ESH and the ISH
 NICE makes recommendations to the NHS on blood pressure monitoring Via the BHS:
 WatchBP Home is the only device with the new Guidelines built in “Patented” is the only device that has been proved that it can detect AF and has been Validated
“Patented”
Is one of only device validated for use in End Stage Renal Disease (ERD) pregnancy – preeclampsia
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
NICE:
Medical technology guidance: WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension.
Issue date: January 2013 – Hypertension Revised Sept 2013 http://guidance.nice.org.uk/MT/InDevelopment http://guidance.nice.org.uk/MT/145
© 2011All Rights Reserved. No copy and distribution without permission

1.1 The case for adopting WatchBP Home A in the NHS, for opportunistically detecting asymptomatic atrial fibrillation during the measurement of blood pressure by primary care professionals, is supported by the evidence.
The available evidence suggests that the device reliably detects atrial fibrillation and may increase the rate of detection when used in primary care. This would allow prophylactic treatment to be given to reduce the incidence of atrial fibrillation-related stroke.
WatchBP Home A should be considered for use in people with suspected hypertension and those being screened or monitored for hypertension, in primary care.
1.2 People suspected of having atrial fibrillation after use of WatchBP
Home A should have an electrocardiogram (ECG) in line with NICE clinical guideline 36, Atrial fibrillation.
© 2011All Rights Reserved. No copy and distribution without permission

1.3 Use of WatchBP Home A in primary care is associated with estimated overall cost savings per person measured, ranging from
£2.98 for those aged between 65 and 74 years to £4.26 for those aged 75 years and over.
There is uncertainty about the costs and benefits for people younger than 65, however it is plausible that using the device in this group will benefit patients and the healthcare system.
As well as cost savings Fatal Strokes that could be prevented per
100,000 screened could be as many as 182, in age groups 65 years
& 75 years were 53 –117 (average 85) and Non Fatal Strokes prevented per 100,000 screened in age groups 65 years & 75 were 28
– 65 (average 47).
© 2011All Rights Reserved. No copy and distribution without permission

In order to obtain more evidence with regard to the clinical evidence of the WatchBP device with Afib detection a clinical study has been performed on behalf of NICE.
In the Hull area (UK) 80 devices were distributed among 15 GP practices. After 6 months 288.000 (of which 54.000 (19%) with the
WatchBP Home) GP patients were screened for AF. This led to 160 newly identified Afib patients of whom 71 patients (44%) were detected with the WatchBP Home. This means that 44% of all newly detected Afib patients were found by only 19% of all GP’s
Results from clinical practice showed that GP’s who used WatchBP detected over 3 times as many patients with Afib as GP’s who used the conventional method
© 2011All Rights Reserved. No copy and distribution without permission

200
150
100
50
0
400
350
300
250
Extrapolating these figures to routine clinical practice showed that
373 patients with Afib would be detected if all GP’s in the Hull area would have used WatchBP for routine clinical blood pressure measurement. This amount is significantly (3.4 times) more than when all GP’s would only rely on wrist palpation as this would result in 109 newly detected patients with AF. From this example from real clinical practice it was shown that using the WatchBP home would lead to an increase in Afib detection by 240%.
1/2 year screening in GP practice
274
WatchBP home A Pulse Palpation
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
 Download Software.
Free Software is available on our web-site which is continually up-dated .
www.watchbp.co.uk
Support
Software
Home WatchBP Home Analyzer
© 2011All Rights Reserved. No copy and distribution without permission

•
•

© 2011All Rights Reserved. No copy and distribution without permission

Device RRP
Mains
Adaptor Single Measurement
3 Consecutive
Measurements
BHS / NHS
Embedded
Guidelines AF Detection PC Link & Free software
Home A £90 £20
Home £70 £20
Home S £60 £20
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
No
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
*Jonathan Mant, David A Fitzmaurice, F D Richard Hobbs,
Sue Jowett, Ellen T Murray, Roger Holder, Michael Davies and Gregory Y H Lip
** Joseph Wiesel, Lorenzo Fitzig, Yehuda Herschman and
Frank C. Messineo
*** GS Stergiou, N Karpettas, A Protogerou, EG Nasothimiou and M Kyriakidis Hypertension Center, Third University
Department of Medicine, Sotiria Hospital, Athens, Greece
© 2011All Rights Reserved. No copy and distribution without permission

Value of WatchBP
I thank you for your time
Edward Gammans
© 2011All Rights Reserved. No copy and distribution without permission